Literature DB >> 28945100

Clinical characteristics of HIV-infected patients with adjudicated heart failure.

Alexandra B Steverson1, Anna E Pawlowski1, Daniel Schneider1, Prasanth Nannapaneni1, Jes M Sanders1, Chad J Achenbach1, Sanjiv J Shah1, Donald M Lloyd-Jones1, Matthew J Feinstein1.   

Abstract

Aims HIV-infected persons may have elevated risks for heart failure, but factors associated with heart failure in the modern era of HIV therapy are insufficiently understood. Despite substantial disagreement between physician-adjudicated heart failure and heart failure diagnosis codes, few studies of HIV cohorts have evaluated adjudicated heart failure. We evaluated associations of HIV viremia, immunosuppression, and cardiovascular risk factors with physician-adjudicated heart failure. Methods and results We analyzed clinical characteristics associated with heart failure in a cohort of 5041 HIV-infected patients receiving care at an urban hospital system between 2000 and 2016. We also evaluated characteristics of HIV-infected patients who screened negative for heart failure, screened positive for possible heart failure but did not have heart failure after adjudication, and had adjudicated heart failure. HIV-infected patients with heart failure ( N = 216) were older and more likely to be black, hypertensive, and have diabetes than HIV-infected patients without heart failure; heart failure with reduced ejection fraction was more common than heart failure with preserved ejection fraction. In our primary analyses restricted to HIV-infected patients whose heart failure diagnoses did not precede their HIV diagnoses ( N = 149), peak HIV viral load ≥100,000 copies/mL (odds ratio (OR) 2.12, 1.28-3.52) and nadir CD4 T-cell count <200 cells/mm3 (OR 2.35, 1.04-5.31) were associated with significantly elevated odds of heart failure. Overall, 30.6% of patients with any diagnosis code of heart failure had adjudicated heart failure. Conclusion Higher peak HIV viremia and lower CD4 cell nadir are associated with significantly elevated odds of heart failure for HIV-infected persons. Physician adjudication of heart failure may be helpful in HIV cohorts.

Entities:  

Keywords:  HIV; Heart failure; adjudication; electronic cohort

Mesh:

Year:  2017        PMID: 28945100      PMCID: PMC5800758          DOI: 10.1177/2047487317732432

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  51 in total

Review 1.  A systematic review of validated methods for identifying heart failure using administrative data.

Authors:  Jane S Saczynski; Susan E Andrade; Leslie R Harrold; Jennifer Tjia; Sarah L Cutrona; Katherine S Dodd; Robert J Goldberg; Jerry H Gurwitz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

Review 2.  Natriuretic peptide testing in heart failure.

Authors:  Han-Na Kim; James L Januzzi
Journal:  Circulation       Date:  2011-05-10       Impact factor: 29.690

3.  Heart failure risk prediction in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Harjit Chahal; David A Bluemke; Colin O Wu; Robyn McClelland; Kiang Liu; Steven J Shea; Gregory Burke; Pelbreton Balfour; David Herrington; PeiBei Shi; Wendy Post; Jean Olson; Karol E Watson; Aaron R Folsom; Joao A C Lima
Journal:  Heart       Date:  2014-11-07       Impact factor: 5.994

Review 4.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.

Authors:  Barry A Borlaug; Walter J Paulus
Journal:  Eur Heart J       Date:  2010-12-07       Impact factor: 29.983

5.  Prevalence of cardiac abnormalities in human immunodeficiency virus infection.

Authors:  W S Levy; G L Simon; J C Rios; A M Ross
Journal:  Am J Cardiol       Date:  1989-01-01       Impact factor: 2.778

6.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

Authors:  Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

7.  Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection.

Authors:  A Herskowitz; D Vlahov; S Willoughby; R E Chaisson; S P Schulman; D A Neumann; K L Baughman
Journal:  Am J Cardiol       Date:  1993-04-15       Impact factor: 2.778

8.  Use of an electronic medical record for the identification of research subjects with diabetes mellitus.

Authors:  Russell A Wilke; Richard L Berg; Peggy Peissig; Terrie Kitchner; Bozana Sijercic; Catherine A McCarty; Daniel J McCarty
Journal:  Clin Med Res       Date:  2007-03

9.  Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013.

Authors:  Matthew J Feinstein; Ehete Bahiru; Chad Achenbach; Christopher T Longenecker; Priscilla Hsue; Kaku So-Armah; Matthew S Freiberg; Donald M Lloyd-Jones
Journal:  Am J Cardiol       Date:  2015-11-06       Impact factor: 2.778

10.  Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of highly active antiretroviral therapy exposure in patients infected with human immunodeficiency virus: a 3T cardiovascular magnetic resonance feasibility study.

Authors:  Mariana Diaz-Zamudio; Damini Dey; Troy LaBounty; Michael Nelson; Zhaoyang Fan; Lidia S Szczepaniak; Bill Pei-Chin Hsieh; Ronak Rajani; Daniel Berman; Debiao Li; Rohan Dharmakumar; W David Hardy; Antonio Hernandez Conte
Journal:  J Cardiovasc Magn Reson       Date:  2015-10-31       Impact factor: 5.364

View more
  14 in total

Review 1.  Epidemiology, pathophysiology, and prevention of heart failure in people with HIV.

Authors:  Arjun Sinha; Matthew Feinstein
Journal:  Prog Cardiovasc Dis       Date:  2020-01-24       Impact factor: 8.194

2.  Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial.

Authors:  Tomas G Neilan; Kim-Lien Nguyen; Vlad G Zaha; Kara W Chew; Leavitt Morrison; Ntobeko A B Ntusi; Mabel Toribio; Magid Awadalla; Zsofia D Drobni; Michael D Nelson; Tricia H Burdo; Marije Van Schalkwyk; Paul E Sax; Daniel J Skiest; Karen Tashima; Raphael J Landovitz; Eric Daar; Alysse G Wurcel; Gregory K Robbins; Robert K Bolan; Kathleen V Fitch; Judith S Currier; Gerald S Bloomfield; Patrice Desvigne-Nickens; Pamela S Douglas; Udo Hoffmann; Steven K Grinspoon; Heather Ribaudo; Rodney Dawson; Matthew Bidwell Goetz; Mamta K Jain; Alberta Warner; Lidia S Szczepaniak; Markella V Zanni
Journal:  J Infect Dis       Date:  2020-07-09       Impact factor: 5.226

3.  Association of Low CD4/CD8 Ratio With Adverse Cardiac Mechanics in Lymphopenic HIV-Infected Adults.

Authors:  Arjun Sinha; Harry Mystakelis; Adovich S Rivera; Maura Manion; Elizabeth Laidlaw; Yolanda Mejia; Adam Rupert; Greg Robby; Virginia Sheikh; Irini Sereti; Matthew J Feinstein
Journal:  J Acquir Immune Defic Syndr       Date:  2020-12-01       Impact factor: 3.731

4.  Variation in Heart Failure Risk by HIV Severity and Sex in People With HIV Infection.

Authors:  Jennifer O Lam; Wendy A Leyden; Thomas K Leong; Michael A Horberg; Kristi Reynolds; Andrew P Ambrosy; Harshith R Avula; Rulin C Hechter; William J Towner; Suma Vupputuri; Alan S Go; Michael J Silverberg
Journal:  J Acquir Immune Defic Syndr       Date:  2022-10-01       Impact factor: 3.771

Review 5.  HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers.

Authors:  Kaku So-Armah; Matthew S Freiberg
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

6.  Predictive Accuracy of Heart Failure-Specific Risk Equations in an Electronic Health Record-Based Cohort.

Authors:  Aakash Bavishi; Matthew Bruce; Hongyan Ning; Priya M Freaney; Peter Glynn; Faraz S Ahmad; Clyde W Yancy; Sanjiv J Shah; Norrina B Allen; Suma X Vupputuri; Laura J Rasmussen-Torvik; Donald M Lloyd-Jones; Sadiya S Khan
Journal:  Circ Heart Fail       Date:  2020-10-23       Impact factor: 8.790

Review 7.  Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study.

Authors:  Javed Butler; Andreas P Kalogeropoulos; Kevin J Anstrom; Priscilla Y Hsue; Raymond J Kim; Rebecca Scherzer; Sanjiv J Shah; Svati H Shah; Eric J Velazquez; Adrian F Hernandez; Patrice Desvigne-Nickens; Eugene Braunwald
Journal:  J Card Fail       Date:  2018-03-02       Impact factor: 5.712

8.  Risks of cardio-vascular diseases among highly active antiretroviral therapy (HAART) treated HIV seropositive volunteers at a treatment centre in Lagos, Nigeria.

Authors:  Oloruntoba Ayodele Ekun; Emmanuel Olusesan Fasela; David Ayoola Oladele; Gideon Odemakpore Liboro; Toyosi Yekeen Raheem
Journal:  Pan Afr Med J       Date:  2021-02-23

9.  Heart Failure Outcomes and Associated Factors Among Veterans With Human Immunodeficiency Virus Infection.

Authors:  Sebhat Erqou; Lan Jiang; Gaurav Choudhary; Michelle Lally; Gerald S Bloomfield; Andrew R Zullo; Theresa I Shireman; Mathew Freiberg; Amy C Justice; James Rudolph; Nina Lin; Wen-Chih Wu
Journal:  JACC Heart Fail       Date:  2020-04-08       Impact factor: 12.544

10.  Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons.

Authors:  Robert A Riestenberg; Andrew Furman; Avery Cowen; Anna Pawlowksi; Daniel Schneider; Alana A Lewis; Sean Kelly; Babafemi Taiwo; Chad Achenbach; Frank Palella; Neil J Stone; Donald M Lloyd-Jones; Matthew J Feinstein
Journal:  Am Heart J       Date:  2018-12-20       Impact factor: 5.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.